Detail Information of Post-Translational Modifications

General Information of Drug Transporter (DT)
DT ID	DTD0034 Transporter Info
Gene Name	SLC18A2
Transporter Name	Vesicular amine transporter 2
Gene ID	6571
UniProt ID	Q05940

Post-Translational Modification of This DT
Overview ofSLC18A2 Modification Sites with Functional and Structural Information
Sequence	M A L S E L A L V R W L Q E S R R S R K L I L F I V F L A L L L D N M L L T V V V P I I P S Y L Y S I K H E K N A T E I Q T A R P V H T A S I S D S F Q S I F S Y Y D N S T M V T G N A T R D L T L H Q T A T Q H M V T N A S A V P S D C P S E D K D L L N E N V Q V G L L F A S K A T V Q L I T N P F I G L L T N R I G Y P I P I F A G F C I M F V S T I M F A F S S S Y A F L L I A R S L Q G I G S S C S S V A G M G M L A S V Y T D D E E R G N V M G I A L G G L A M G V L V G P P F G S V L Y E F V G K T A P F L V L A A L V L L D G A I Q L F V L Q P S R V Q P E S Q K G T P L T T L L K D P Y I L I A A G S I C F A N M G I A M L E P A L P I W M M E T M C S R K W Q L G V A F L P A S I S Y L I G T N I F G I L A H K M G R W L C A L L G M I I V G V S I L C I P F A K N I Y G L I A P N F G V G F A I G M V D S S M M P I M G Y L V D L R H V S V Y G S V Y A I A D V A F C M G Y A I G P S A G G A I A K A I G F P W L M T I I G I I D I L F A P L C F F L R S P P A K E E K M A I L M D H N C P I K T K M Y T Q N N I Q S Y P I G E D E E S E S D
PTM type	X-Acetylation X-Disulfide bond X-N-glycosylation X-Oxidation X-Phosphorylation X-Phosphorylation X-S-nitrosylation X: Amino Acid

Acetylation
Lysine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC18A2			[1]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	479
Experimental Method	Co-Immunoprecipitation
Detailed Description	Acetylation at SLC18A2 Lysine 479 has the potential to affect its expression or activity.
Disulfide bond
Cystine	2 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC18A2			[2]
Role of PTM	Potential impacts
Modified Residue	Cystine	Modified Location	117
Experimental Method	Co-Immunoprecipitation
Detailed Description	Disulfide bond (-SSR) at SLC18A2 Cystine 117 has the potential to affect its expression or activity.
PTM Phenomenon2	Have the potential to influence SLC18A2			[2]
Role of PTM	Potential impacts
Modified Residue	Cystine	Modified Location	324
Experimental Method	Co-Immunoprecipitation
Detailed Description	Disulfide bond (-SSR) at SLC18A2 Cystine 324 has the potential to affect its expression or activity.
N-glycosylation
Asparagine	2 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC18A2			[3]
Role of PTM	Potential impacts
Modified Residue	Asparagine	Modified Location	84
Experimental Method	Co-Immunoprecipitation
Detailed Description	N-linked Glycosylation at SLC18A2 Asparagine 84 has the potential to affect its expression or activity.
PTM Phenomenon2	Have the potential to influence SLC18A2			[3]
Role of PTM	Potential impacts
Modified Residue	Asparagine	Modified Location	91
Experimental Method	Co-Immunoprecipitation
Detailed Description	N-linked Glycosylation at SLC18A2 Asparagine 91 has the potential to affect its expression or activity.
Oxidation
Cystine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC18A2			[4]
Role of PTM	Potential impacts
Modified Residue	Cystine	Modified Location	488
Experimental Method	Co-Immunoprecipitation
Detailed Description	Oxidation at SLC18A2 Cystine 488 has the potential to affect its expression or activity.
Phosphorylation
Serine	8 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	.			[5]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	15
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC18A2 Serine 15 has the potential to affect its expression or activity.
PTM Phenomenon2	.			[5]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	15
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC18A2 Serine 15 has the potential to affect its expression or activity.
PTM Phenomenon3	Have the potential to influence SLC18A2			[6]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	50
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC18A2 Serine 50 has the potential to affect its expression or activity.
PTM Phenomenon4	Have the potential to influence SLC18A2			[7]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	111
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC18A2 Serine 111 has the potential to affect its expression or activity.
PTM Phenomenon5	Have the potential to influence SLC18A2			[7]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	119
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC18A2 Serine 119 has the potential to affect its expression or activity.
PTM Phenomenon6	Have the potential to influence SLC18A2			[8], [9]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	240
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC18A2 Serine 240 has the potential to affect its expression or activity.
PTM Phenomenon7	Have the potential to influence SLC18A2			[10], [11]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	511
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC18A2 Serine 511 has the potential to affect its expression or activity.
PTM Phenomenon8	Have the potential to influence SLC18A2			[10], [11]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	513
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC18A2 Serine 513 has the potential to affect its expression or activity.
S-nitrosylation
Cystine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC18A2			[12]
Role of PTM	Potential impacts
Modified Residue	Cystine	Modified Location	488
Experimental Method	Co-Immunoprecipitation
Detailed Description	S-nitrosylation (-SNO) at SLC18A2 Cystine 488 has the potential to affect its expression or activity.

References
1	Deep, Quantitative Coverage of the Lysine Acetylome Using Novel Anti-acetyl-lysine Antibodies and an Optimized Proteomic Workflow. Mol Cell Proteomics. 2015 Sep;14(9):2429-40.
2	iCysMod: an integrative database for protein cysteine modifications in eukaryotes. Brief Bioinform. 2021 Sep 2;22(5):bbaa400. (ID: Q05940)
3	dbPTM in 2022: an updated database for exploring regulatory networks and functional associations of protein post-translational modifications. Nucleic Acids Res. 2022 Jan 7;50(D1):D471-D479. (ID: VMAT2_HUMAN)
4	A Quantitative Tissue-Specific Landscape of Protein Redox Regulation during Aging. Cell. 2020 Mar 5;180(5):968-983.e24.
5	ActiveDriverDB: human disease mutations and genome variation in post-translational modification sites of proteins. Nucleic Acids Res. 2018;46(D1):D901-D910.
6	Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics. 2014 Jul;13(7):1690-704.
7	iTRAQ labeling is superior to mTRAQ for quantitative global proteomics and phosphoproteomics. Mol Cell Proteomics. 2012 Jun;11(6):M111.014423.
8	Systematic functional prioritization of protein posttranslational modifications. Cell. 2012 Jul 20;150(2):413-25.
9	Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal. 2009 Aug 18;2(84):ra46.
10	Phosphoproteins in extracellular vesicles as candidate markers for breast cancer. Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3175-3180.
11	Global phosphoproteome analysis of human bone marrow reveals predictive phosphorylation markers for the treatment of acute myeloid leukemia with quizartinib. Leukemia. 2014 Mar;28(3):716-9.
12	Extensive protein S-nitrosylation associated with human pancreatic ductal adenocarcinoma pathogenesis. Cell Death Dis. 2019 Dec 4;10(12):914.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.

Detail Information of Post-Translational Modifications

Visitor Map

Correspondence